MiniMed’s Independence Needs an Operating Scorecard

Original analysis · October 16, 2026.

On October 15, MiniMed announced Amy Bricker and Tim Main’s board appointments. Kevin Lofton remains chair of the nine-member board.

Our reading is that this is a useful moment to change the question asked of a newly independent business. Who controls decisions matters. The next test is whether the organization can carry out those decisions through processes it can operate, pay for and supervise. A refreshed board alone cannot answer that question.

Read the operating contracts beside the governance news

The March services contract requires exit plans; migration support needs agreed scope, schedule and cost. Specified migration work is charged at hourly rates plus 15%.

The manufacturing agreement describes interim supply while MiniMed develops alternative sourcing or production. Project terms beyond 24 months from March 1, 2026 require Medtronic’s consent.

These are contractual provisions, not an October progress report. Our proposed assessment therefore starts with a service-by-service record: the process being replaced, its accountable owner, the replacement’s acceptance test and the evidence needed to close the old arrangement. Counting signed contracts or appointed leaders would leave the most practical questions unanswered.

Consider a hypothetical billing migration. A new system can be installed while invoices still require manual corrections. A meaningful handover would test an order through invoicing, reconciliation and collection, then record exceptions that need a person to intervene. This is an illustration of how to assess a transition, not a claim that MiniMed has a billing problem.

Separate three kinds of cost

For public-market readers, we would request a bridge between the old arrangement and the replacement, with three distinct categories: recurring charges removed, recurring costs introduced and temporary cash spent to make the change. An expense disappearing from one line does not establish a saving if an equivalent amount reappears elsewhere.

This also changes how timing should be read. Spending on two processes at once could be a deliberate rehearsal rather than evidence of failure. Conversely, a rapid cutover could look inexpensive before errors emerge. The more informative comparison is the cost of reaching an accepted operating state, including the work needed to resolve exceptions, against a plan that was defined beforehand.

A hypothetical example makes the distinction clear. If an old service costs ten units and its replacement costs eight, the apparent recurring saving is two. But twenty units of migration spending would require ten periods of that saving to recover, before considering any other effects. These are illustrative units, not company figures or an earnings forecast. They explain why an exit date and a cash-payback date are different milestones.

Give the board a handover test

We would look for reporting that distinguishes preparation, acceptance and stable operation. Preparation shows that people and systems are available. Acceptance shows that a named owner has checked a defined task. Stable operation requires repeated performance after the handover, rather than a successful demonstration on one chosen day.

The October 5 prospectus warns that replacement services may not match Medtronic’s terms. That warning identifies uncertainty; it does not establish that a replacement has failed.

A useful board discussion would connect exceptions to decisions. Which unresolved issue blocks a handover? Who has authority to accept it? What evidence would justify continuing, delaying or reversing the change? Publishing a giant checklist is unnecessary. A consistent explanation of completed milestones, changed assumptions and remaining dependencies would be more useful than an undifferentiated percentage-complete figure.

The documents reviewed do not establish which individual services remain active on October 16, their current replacement costs or the status of every migration. We therefore make no claim that a deadline has been missed or that margins will improve. The analytical test is narrower: can the company show that a replacement works and explain its full economic cost? That is how operational independence becomes observable.